NEW YORK (AP) — All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Dr. Lbiati’s appointment signals a new chapter for Hepion—one focused on strategic renewal, value creation, and diagnostic innovation in areas of significant unmet clinical need, including celiac ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The monoclonal antibody nirsevimab, though not a vaccine, is approved by the FDA for the prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their ...

The FDA halted enrollment of young children in RSV vaccine trials after five infants in one study developed severe RSV infections. An FDA panel asked for additional data to better understand what ...

Arexvy In May 2023, Arexvy, from GSK, became the first vaccine approved by the U.S. Food and Drug Administration (FDA) to fight RSV, using an inactivated preF protein combined with an adjuvant (an ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years and older, as well as for 60- to 74-year-olds who are at increased risk ...